DiaSorin SpA (DiaSorin) is a medical devices company focused on developing, manufacturing, and marketing immunodiagnostic and molecular diagnostic reagent kits and systems. The company offers in vitro diagnostic products for various clinical segments, including infectious diseases, endocrinology, gastrointestinal infections, autoimmunity, hypertension, emergency/ sepsis, bone metabolism, and oncology. It offers its products to hospitals and private testing laboratories. The company classifies its products into three categories: immunodiagnostics, molecular diagnostics, and licensed technologies.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

DiaSorin is engaged in R&D to drive innovation in the diagnostics industry. The company focuses on developing new diagnostic tools and solutions that address emerging clinical needs and market trends. With a team of over 400 researchers primarily based in Italy and the United States, DiaSorin invests significantly in R&D to maintain its leadership in the in-vitro diagnostics and Life Sciences sector. DiaSorin's R&D units are responsible for designing assays, instruments, and platforms that shape the future of diagnostics. These teams work at the frontier of immunoassays, molecular technologies, and licensed innovations, collaborating across disciplines and geographies to translate scientific ideas into clinical tools. DiaSorin operates 9 R&D centers located across North America, Europe, and Asia. In FY2025, the company spent EUR95 million on R&D, which as a percentage of revenue, stood at 7.9% and grew 3.8% YoY.